Ahmar is currently the Group Medical Director for Respiratory US Medical Affairs at Genentech. Among other things, Ahmar leads the scientists that work on omalizumab and pirfenidone.

One of the major projects that Ahmar is working on is the Genentech/Novartis collaboration with the NIH and the Consortium for Food Allergy on the project to assess the efficacy of omalizumab for food allergies.

During the 3 years prior to joining Genentech, Ahmar was the Global Medical Affairs Lead in GSK's Respiratory Franchise overseeing medical affairs teams for respiratory products mainly in the area of COPD.

Previously, Ahmar has worked at Pfizer Inc., where he held senior management positions in the Health Outcome Services Group and in Medical Affairs. While in the Health Outcomes Department, he led a staff of clinical researchers in developing clinical decision support software and in implementing clinical studies, both in the US and internationally. From 2007 to 2012, he was the Senior Medical Director for the Respiratory Medical Affairs Group at Pfizer working primarily on tiotropium.

Ahmar got his medical training in Pakistan and an MBA in the US from Boston University. He practiced for a number of years as an internist and family physician. He has also had a career as a faculty member at an Academic Medical Center and in the Medical Directors office in a US health plan. In addition, Ahmar has worked on quality of care initiatives and medical consensus building as a provider to the RAND Corporation prior to joining industry.